sunitinib stada 25mg tvrdá tobolka
stada arzneimittel ag, bad vilbel array - 17420 sunitinib - tvrdá tobolka - 25mg - sunitinib
sunitinib stada 50mg tvrdá tobolka
stada arzneimittel ag, bad vilbel array - 17420 sunitinib - tvrdá tobolka - 50mg - sunitinib
sunitinib vipharm 12,5mg tvrdá tobolka
vipharm s.a., ożarów mazowiecki array - 17468 sunitinib-malÁt - tvrdá tobolka - 12,5mg - sunitinib
sunitinib vipharm 25mg tvrdá tobolka
vipharm s.a., ożarów mazowiecki array - 17468 sunitinib-malÁt - tvrdá tobolka - 25mg - sunitinib
sunitinib vipharm 50mg tvrdá tobolka
vipharm s.a., ożarów mazowiecki array - 17468 sunitinib-malÁt - tvrdá tobolka - 50mg - sunitinib
sunitinib zentiva 12,5mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 12,5mg - sunitinib
sunitinib zentiva 25mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 25mg - sunitinib
sunitinib zentiva 37,5mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 37,5mg - sunitinib
sunitinib zentiva 50mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 50mg - sunitinib
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastická činidla - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.